Literature DB >> 2432091

Autoantibody to RNA polymerase I in scleroderma sera.

G Reimer, K M Rose, U Scheer, E M Tan.   

Abstract

Autoantibodies to components of the nucleolus are a unique serological feature of patients with scleroderma. There are autoantibodies of several specificities; one type produces a speckled pattern of nucleolar staining in immunofluorescence. In actinomycin D and 5,6-dichloro-beta-D-ribofuranosylbenzimidazole-treated Vero cells, staining was restricted to the fibrillar and not the granular regions. By double immunofluorescence, specific rabbit anti-RNA polymerase I antibodies stained the same fibrillar structures in drug-segregated nucleoli as scleroderma sera. Scleroderma sera immunoprecipitated 13 polypeptides from [35S]methionine-labeled HeLa cell extract with molecular weights ranging from 210,000 to 14,000. Similar polypeptides were precipitated by rabbit anti-RNA polymerase I antibodies, and their common identities were confirmed in immunoabsorption experiments. Microinjection of purified IgG from a patient with speckled nucleolar staining effectively inhibited ribosomal RNA transcription. Autoantibodies to RNA polymerase I were restricted to certain patients with scleroderma and were not found in other autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2432091      PMCID: PMC423987          DOI: 10.1172/JCI112809

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma.

Authors:  A S Douvas; M Achten; E M Tan
Journal:  J Biol Chem       Date:  1979-10-25       Impact factor: 5.157

2.  Antinucleolar antibodies in human sera.

Authors:  J L Pinnas; J D Northway; E M Tan
Journal:  J Immunol       Date:  1973-10       Impact factor: 5.422

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Drug-induced changes in the interphase nucleus.

Authors:  W Bernhard
Journal:  Adv Cytopharmacol       Date:  1971-05

5.  Antibodies to small nuclear RNAs complexed with proteins are produced by patients with systemic lupus erythematosus.

Authors:  M R Lerner; J A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

6.  Fibrillarin: a new protein of the nucleolus identified by autoimmune sera.

Authors:  R L Ochs; M A Lischwe; W H Spohn; H Busch
Journal:  Biol Cell       Date:  1985       Impact factor: 4.458

7.  Interaction between VA RNA and the lupus antigen La: formation of a ribonucleoprotein particle in vitro.

Authors:  A M Francoeur; M B Mathews
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

8.  Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus.

Authors:  M R Lerner; N C Andrews; G Miller; J A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

9.  Nucleolar necklaces in chick embryo fibroblast cells. I. Formation of necklaces by dichlororibobenzimidazole and other adenosine analogues that decrease RNA synthesis and degrade preribosomes.

Authors:  D Granick
Journal:  J Cell Biol       Date:  1975-05       Impact factor: 10.539

10.  Nucleolar necklaces in chick embryo fibroblast cells. II. Microscope observations of the effect of adenosine analogues on nucleolar necklace formation.

Authors:  D Granick
Journal:  J Cell Biol       Date:  1975-05       Impact factor: 10.539

View more
  65 in total

Review 1.  Systemic sclerosis: an autoantibody mosaic.

Authors:  C C Bunn; C M Black
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 2.  Relative paradigms between autoantibodies in lupus and autoantibodies in cancer.

Authors:  E M Tan; F-D Shi
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

3.  Dynamic sorting of nuclear components into distinct nucleolar caps during transcriptional inhibition.

Authors:  Yaron Shav-Tal; Janna Blechman; Xavier Darzacq; Cristina Montagna; Billy T Dye; James G Patton; Robert H Singer; Dov Zipori
Journal:  Mol Biol Cell       Date:  2005-03-09       Impact factor: 4.138

4.  UBF binding in vivo is not restricted to regulatory sequences within the vertebrate ribosomal DNA repeat.

Authors:  Audrey C O'Sullivan; Gareth J Sullivan; Brian McStay
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

5.  The cytoplasmic zinc finger protein ZPR1 accumulates in the nucleolus of proliferating cells.

Authors:  Z Galcheva-Gargova; L Gangwani; K N Konstantinov; M Mikrut; S J Theroux; T Enoch; R J Davis
Journal:  Mol Biol Cell       Date:  1998-10       Impact factor: 4.138

Review 6.  Autoantibodies to components of the mitotic apparatus.

Authors:  J B Rattner; G J Mack; M J Fritzler
Journal:  Mol Biol Rep       Date:  1998-07       Impact factor: 2.316

7.  A nucleolar auto-antigen is part of a major chromosomal surface component.

Authors:  Y Yasuda; G G Maul
Journal:  Chromosoma       Date:  1990-04       Impact factor: 4.316

8.  Identification of protein components reactive with anti-PM/Scl autoantibodies.

Authors:  C Gelpi; A Algueró; M Angeles Martinez; S Vidal; C Juarez; J L Rodriguez-Sanchez
Journal:  Clin Exp Immunol       Date:  1990-07       Impact factor: 4.330

9.  Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera.

Authors:  M Satoh; A K Ajmani; T Ogasawara; J J Langdon; M Hirakata; J Wang; W H Reeves
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

10.  Antibodies against a novel nucleolar and cytoplasmic antigen (p105-p42) present in the sera of patients with a subset of rheumatoid arthritis (RA) with signs of scleroderma.

Authors:  M Labrador; A Algueró; C Díaz; C Geli; E Pérez; J García-Valero; J L Rodriguez-Sanchez; C Gelpí
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.